Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03361748 · OUTCOME

Complete Response Rate

Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma · Source last updated 2025-05-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
From first dose to 24 Months

What was measured

Percentage of participants who achieved CR or sCR according to IMWG Uniform Response Criteria for Multiple Myeloma as assessed by an IRC.

Analysis population: All Treated Participants

Groups in this outcome

BB2121

BB2121

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
BB2121137

Reported measurements

Source class 1
Values in Percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
BB212134.3Not reported26.442.3Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        26.4
        upper Limit
        42.3
        value
        34.3
denoms
  1. counts
    1. group Id
      OG000
      value
      137
    units
    Participants
description
Percentage of participants who achieved CR or sCR according to IMWG Uniform Response Criteria for Multiple Myeloma as assessed by an IRC.
dispersion Type
95% Confidence Interval
groups
  1. description
    BB2121
    id
    OG000
    title
    BB2121
param Type
NUMBER
population Description
All Treated Participants
reporting Status
POSTED
time Frame
From first dose to 24 Months
title
Complete Response Rate
type
SECONDARY
unit Of Measure
Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice